Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
AstraZeneca
Colorcon
McKinsey
Harvard Business School

Last Updated: October 6, 2022

Details for Patent: 8,808,737


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,808,737 protect, and when does it expire?

Patent 8,808,737 protects OPANA ER and is included in two NDAs.

Summary for Patent: 8,808,737
Title:Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
Abstract: The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician that the bioavailability of oxymorphone is increased in patients with renal impairment.
Inventor(s): Ahdieh; Harry (Lincoln University, PA)
Assignee: Endo Pharmaceuticals Inc. (Malvern, PA)
Application Number:12/716,973
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,808,737
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,808,737

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 DISCN Yes No See Plans and Pricing See Plans and Pricing DOSE MODIFICATION FOR RENAL IMPAIRMENT See Plans and Pricing
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-001 Dec 9, 2011 DISCN Yes No See Plans and Pricing See Plans and Pricing METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE See Plans and Pricing
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-005 Feb 29, 2008 DISCN Yes No See Plans and Pricing See Plans and Pricing DOSE MODIFICATION FOR RENAL IMPAIRMENT See Plans and Pricing
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-002 Dec 9, 2011 DISCN Yes No See Plans and Pricing See Plans and Pricing METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE See Plans and Pricing
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-002 Jun 22, 2006 DISCN Yes No See Plans and Pricing See Plans and Pricing DOSE MODIFICATION FOR RENAL IMPAIRMENT See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Dow
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.